Tiffany Braley, MD
Neurology · Ann Arbor, MINPI 1467579177
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,793 of the $6,815 with a category attached, or 99.7%. 3 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 55.9% of the total. Reporting peaked in 2021 at $3,808 and has fallen 99.4% since, to $22 in 2023.
Across 4 payments — averaging $1703.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$4K
- Jazz Pharmaceuticals Inc.$3K
- TG Therapeutics, Inc.$22
Across 43 payments — averaging $8772.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$150K
- Sanofi$118K
- Novartis$109K
What the payments were for
- Consulting fees$6,793100%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 1 | $3,808 |
| Jazz Pharmaceuticals Inc. | 2 | $2,985 |
| TG Therapeutics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUNOSI$2,985
How this compares
$6,815 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 14 | $144,287 |
| CopaxoneGlatiramer Acetate | 25 | $137,296 |
| Kesimpta PenOfatumumab | 14 | $126,457 |
| VumerityDiroximel Fumarate | 11 | $94,464 |
| Glatiramer Acetate | 29 | $64,527 |
| Dimethyl Fumarate | 57 | $21,666 |
| Dalfampridine ErDalfampridine | 45 | $20,942 |
| Modafinil | 29 | $2,011 |
| Gabapentin | 46 | $1,833 |
| Baclofen | 39 | $1,346 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $680 |
| Amitriptyline Hcl | 13 | $295 |
Paid to pharmacies, not to this prescriber.
Other neurology in Ann Arbor
- Wade CooperAnn Arbor$991K
- James WeintraubAnn Arbor$194K
- Maysa HamadeAnn Arbor$90K
- Kelvin ChouAnn Arbor$52K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.